KALYDECO ORAL GRANULES Rx
Generic Name and Formulations:
Ivacaftor 50mg, 75mg; per packet.
Indications for KALYDECO ORAL GRANULES:
Treatment of cystic fibrosis (CF) in patients ≥2yrs who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data.
Adults and Children:
<2yrs: not recommended. Oral granules should be mixed with 1 tsp (5mL) of soft-food or liquid (eg, yogurt, applesauce, milk, or juice) and completely consumed. Take with fat-containing food (eg, eggs, butter, peanut butter, cheese pizza, dairy products). 2–<6yrs: (<14kg): 50mg packet every 12 hours; (≥14kg): 75mg packet every 12 hours. ≥6yrs: 150mg tab every 12 hours. Concomitant strong CYP3A inhibitors: 150mg tab or 50mg packet (<14kg) or 75mg packet (≥14kg) twice weekly. Concomitant moderate CYP3A inhibitors: 150mg tab or 50mg packet (<14kg) or 75mg packet (≥14kg) once daily. Moderate hepatic impairment: 150mg tab or 50mg packet (<14kg) or 75mg packet (≥14kg) once daily. Severe hepatic impairment: 150mg tab or 1 packet once daily or less frequently.
If genotype is unknown, use an FDA-cleared CF mutation test to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions. Assess ALT/AST levels prior to initiating therapy, every 3 months during the first year of treatment, and annually thereafter. History of ALT/AST elevations: monitor LFTs more frequently. If increased ALT/AST levels develop, monitor closely until abnormalities resolved. Interrupt dosing if ALT/AST is >5xULN; after resolution, consider restarting. Perform baseline and follow-up eye exams. Hepatic impairment. Severe renal impairment or ESRD. Pregnancy. Nursing mothers.
Concomitant strong CYP3A inducers (eg, rifampin, rifabutin, phenobarbital, carbamazepine, phenytoin, St. John’s Wort): not recommended. Potentiated by strong CYP3A inhibitors (eg, ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin, clarithromycin) and moderate CYP3A inhibitors (eg, fluconazole, erythromycin). May be potentiated by grapefruit and Seville oranges; avoid. Potentiates CYP3A and/or P-gp substrates (eg, digoxin, cyclosporine, tacrolimus).
Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator.
Headache, oropharyngeal pain, upper respiratory tract infection, nasal congestion, abdominal pain, nasopharyngitis, diarrhea, rash, nausea, dizziness.
Tabs—56, 60; Oral granules—56
Psychiatry Advisor Articles
- ADHD, Comorbid Bipolar Disorder Share Similar Neurocognitive Profiles
- Anxiety Prevention Interventions: How Effective Are They?
- No Evidence of Personality Changes Prior to Developing Cognitive Impairment, Dementia
- Antidepressant Use and Dementia Risk in the Elderly
- Sleep Apnea Implant Device Receives FDA Approval
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- Physicians Spend Nearly 6 Hours on EHR Tasks Per Day
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Maternal Glucocorticoid Exposure Not Associated With ADHD in Offspring
- Ketamine Not Associated With PTSD Development in Military Trauma Setting
- Duration of Untreated Depression Predicts Depression Severity
- Asenapine Prevents Recurrence of Mood Events in Bipolar Disorder
- Cognitive Dysfunction a Sign of Prodromal Parkinson Disease